Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas.
Strahlenther Onkol
; 185(8): 524-9, 2009 Aug.
Article
in En
| MEDLINE
| ID: mdl-19652936
ABSTRACT
PURPOSE:
To assess the feasibility and effectiveness of perioperative high-dose-rate brachytherapy for recurrent malignant gliomas. PATIENTS ANDMETHODS:
Between 2005 and 2008, 21 patients (14 males and seven females) with relapsed malignant glioma underwent a second surgery followed by a brachytherapy implant in the surgical cavity. Median age was 60 years, and median Karnofsky performance status 80. A single fraction of 18 Gy specified at 5 mm depth was administered perioperatively. Then, the applicator was removed nonsurgically. Mean postoperative hospitalization time was 3 days.RESULTS:
At the time of analysis, 15 patients (71%) had died and six (29%) were alive. Median follow-up was 32.3 months. Median overall survival from diagnosis amounted to 21.7 months. Median survival after recurrence was 8.0 months, and 6-month progression-free survival 42%. Patients were stratified into classes according to the prognostic recursive partitioning analysis.CONCLUSION:
Perioperative brachytherapy has proven to be safe and well tolerated in patients with recurrent malignant glioma. No severe toxicity was reported, and the treatment has proven to be effective in symptomatic recurrences of malignant gliomas.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Astrocytoma
/
Brachytherapy
/
Brain Neoplasms
/
Glioblastoma
/
Neoplasm Recurrence, Local
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Strahlenther Onkol
Journal subject:
NEOPLASIAS
/
RADIOTERAPIA
Year:
2009
Document type:
Article
Affiliation country:
Italy